Literature DB >> 26062596

University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (morning panel discussion).

Michael Daniels, Constantine Frangakis, Vivek Charu, Debashis Ghosh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26062596      PMCID： PMC4655088          DOI： 10.1177/1740774515590090

Source DB:  PubMed          Journal:  Clin Trials        ISSN： 1740-7745            Impact factor:   2.486


× No keyword cloud information.
  12 in total

1.  Identifiability and exchangeability for direct and indirect effects.

Authors:  J M Robins; S Greenland
Journal:  Epidemiology       Date:  1992-03       Impact factor: 4.822

2.  Analysis of randomized comparative clinical trial data for personalized treatment selections.

Authors:  Tianxi Cai; Lu Tian; Peggy H Wong; L J Wei
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

3.  Selecting optimal treatment in clinical trials using covariate information.

Authors:  D P Byar; D K Corle
Journal:  J Chronic Dis       Date:  1977-07

4.  Consistent causal effect estimation under dual misspecification and implications for confounder selection procedures.

Authors:  Susan Gruber; Mark J van der Laan
Journal:  Stat Methods Med Res       Date:  2012-02-23       Impact factor: 3.021

5.  Using latent outcome trajectory classes in causal inference.

Authors:  Booil Jo; Chen-Pin Wang; Nicholas S Ialongo
Journal:  Stat Interface       Date:  2009-01-01       Impact factor: 0.582

6.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

7.  Surrogate markers for time-varying treatments and outcomes.

Authors:  Jesse Y Hsu; Edward H Kennedy; Jason A Roy; Alisa J Stephens-Shields; Dylan S Small; Marshall M Joffe
Journal:  Clin Trials       Date:  2015-05-06       Impact factor: 2.486

8.  Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  Clin Trials       Date:  2014-11-10       Impact factor: 2.486

9.  Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Authors:  Anton P Porsteinsson; Lea T Drye; Bruce G Pollock; D P Devanand; Constantine Frangakis; Zahinoor Ismail; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; David M Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos
Journal:  JAMA       Date:  2014-02-19       Impact factor: 56.272

10.  Surrogate endpoints.

Authors:  S S Ellenberg
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.